{
    "organizations": [],
    "uuid": "0b9b0fc2ebb183cfdb94817c338905514a16c454",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-cosmo-pharmaceuticals-fda-accepts/brief-cosmo-pharmaceuticals-fda-accepts-new-drug-application-submission-for-rifamycin-sv-mmx-idUSFWN1SP05K",
    "ord_in_thread": 0,
    "title": "BRIEF-Cosmo Pharmaceuticals: FDA Accepts New Drug Application Submission For Rifamycin SV MMX",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 18 (Reuters) - Cosmo Pharmaceuticals NV:\n* FDA ACCEPTS NEW DRUG APPLICATION SUBMISSION FOR RIFAMYCIN SV MMX AND SETS PDUFA DATE FOR NOVEMBER 16, 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-05-18T13:04:00.000+03:00",
    "crawled": "2018-05-18T08:08:53.024+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "cosmo",
        "pharmaceutical",
        "nv",
        "fda",
        "accepts",
        "new",
        "drug",
        "application",
        "submission",
        "rifamycin",
        "sv",
        "mmx",
        "set",
        "pdufa",
        "date",
        "november",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}